Brown Advisory Inc. Has $4.03 Million Stake in Ascendis Pharma A/S (NASDAQ:ASND)

Brown Advisory Inc. lowered its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 28.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 25,860 shares of the biotechnology company's stock after selling 10,426 shares during the quarter. Brown Advisory Inc.'s holdings in Ascendis Pharma A/S were worth $4,031,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the company. RA Capital Management L.P. boosted its stake in shares of Ascendis Pharma A/S by 4.1% during the 4th quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company's stock valued at $1,392,221,000 after buying an additional 402,316 shares during the period. Avoro Capital Advisors LLC boosted its stake in shares of Ascendis Pharma A/S by 2.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 5,103,055 shares of the biotechnology company's stock valued at $702,538,000 after buying an additional 114,167 shares during the period. Artisan Partners Limited Partnership boosted its stake in shares of Ascendis Pharma A/S by 0.9% during the 4th quarter. Artisan Partners Limited Partnership now owns 4,450,420 shares of the biotechnology company's stock valued at $612,689,000 after buying an additional 39,309 shares during the period. Janus Henderson Group PLC boosted its stake in shares of Ascendis Pharma A/S by 4.6% during the 4th quarter. Janus Henderson Group PLC now owns 4,380,382 shares of the biotechnology company's stock valued at $602,910,000 after buying an additional 193,688 shares during the period. Finally, Capital International Investors boosted its stake in shares of Ascendis Pharma A/S by 35.7% during the 4th quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company's stock valued at $394,183,000 after buying an additional 753,859 shares during the period.

Ascendis Pharma A/S Trading Down 0.1%

Shares of NASDAQ ASND traded down $0.14 during mid-day trading on Tuesday, hitting $174.75. The company had a trading volume of 276,916 shares, compared to its average volume of 504,615. The company has a market capitalization of $10.68 billion, a PE ratio of -27.83 and a beta of 0.38. The firm has a 50-day simple moving average of $168.27 and a two-hundred day simple moving average of $153.60. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $183.00.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The company had revenue of $123.97 million during the quarter, compared to analyst estimates of $98.56 million. Sell-side analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ASND has been the topic of a number of recent analyst reports. Evercore ISI raised their price objective on Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an "outperform" rating in a research note on Friday, May 2nd. Oppenheimer reissued an "outperform" rating and set a $224.00 price objective (up previously from $215.00) on shares of Ascendis Pharma A/S in a research report on Friday, June 13th. Cantor Fitzgerald reissued an "overweight" rating and set a $200.00 price objective on shares of Ascendis Pharma A/S in a research report on Monday, May 12th. Morgan Stanley began coverage on Ascendis Pharma A/S in a research report on Thursday, July 3rd. They set an "overweight" rating and a $250.00 price objective for the company. Finally, Bank of America boosted their price objective on Ascendis Pharma A/S from $201.00 to $216.00 and gave the stock a "buy" rating in a research report on Monday, June 9th. One analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $223.07.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.